CliffBio
biologic

Adynovate

Antihemophilic Factor (Recombinant), PEGylated

Loss of exclusivityNovember 2027projected — 12-year biologic exclusivity estimate
CompanyTakeda Pharmaceuticals U.S.A., Inc.

Drug detail

Brand nameAdynovate
Active ingredientAntihemophilic Factor (Recombinant), PEGylated
Strength500IU
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalNovember 2015
Marketing statusRx

More from Takeda Pharmaceuticals U.S.A., Inc.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Adynovate patent cliff — loss of exclusivity November 2027 | CliffBio